Clinical Infectious Diseases (CID)
Volume 60 Issue 10 May 15, 2015
http://cid.oxfordjournals.org/content/current

.
Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Invasive Disease and Hospital-Treated Pneumonia Among People Aged ≥65 Years: A Retrospective Case-Control Study
Maya Leventer-Roberts, Becca S. Feldman, Ilan Brufman, Chandra J. Cohen-Stavi, Moshe Hoshen, and Ran D. Balicer
Clin Infect Dis. (2015) 60 (10): 1472-1480 doi:10.1093/cid/civ096
Abstract
This large, population-based study confirmed that the 23-valent pneumococcal polysaccharide vaccine is effective against invasive pneumococcal disease among adults aged ≥65 years. However, the vaccine was not found to be effective in preventing community-acquired pneumonia requiring hospitalization.

.
Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003–2013
Lakshmi Sukumaran, Michael M. McNeil, Pedro L. Moro, Paige W. Lewis, Scott K. Winiecki, and Tom T. Shimabukuro
Clin Infect Dis. (2015) 60 (10): e58-e65 doi:10.1093/cid/civ061
Abstract
Limited data exist on the safety of measles, mumps, and rubella (MMR) vaccine in adults. In our review of reports to the Vaccine Adverse Event Reporting System, no new or unexpected safety concerns for adult MMR vaccination were detected.